医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
4期
64
,共1页
徐洁平%王博智%姚伟%林丽霞
徐潔平%王博智%姚偉%林麗霞
서길평%왕박지%요위%림려하
多西他赛%表柔吡星%化疗%乳腺癌%临床疗效%毒副作用
多西他賽%錶柔吡星%化療%乳腺癌%臨床療效%毒副作用
다서타새%표유필성%화료%유선암%림상료효%독부작용
docetaxel%pirarubicin(THP)%chemotherapy%breast cancer%efficacy and safety
目的探讨多西他赛联合表柔吡星治疗乳腺癌的疗效及不良反应.方法将120例晚期乳腺癌患者随机分为观察组和对照组,每组60例.观察组采用多西他赛联合表柔吡星治疗;对照组采用环磷酰胺联合5-氟尿嘧啶、阿霉素治疗,比较两组患者的临床疗效及毒副反应.结果观察组CR 8例, PR36例,近期总有效率为73.3%(44/60),显著高于对照组的近期总有效率26.7%(16/60)( P <0.05);不良反应为脱发、厌食疲乏、恶心呕吐、白细胞下降等,多数患者能耐受.结论多西他赛联合表柔吡星治疗乳腺癌的疗效肯定,毒副反应小,患者能耐受,值得推广.
目的探討多西他賽聯閤錶柔吡星治療乳腺癌的療效及不良反應.方法將120例晚期乳腺癌患者隨機分為觀察組和對照組,每組60例.觀察組採用多西他賽聯閤錶柔吡星治療;對照組採用環燐酰胺聯閤5-氟尿嘧啶、阿黴素治療,比較兩組患者的臨床療效及毒副反應.結果觀察組CR 8例, PR36例,近期總有效率為73.3%(44/60),顯著高于對照組的近期總有效率26.7%(16/60)( P <0.05);不良反應為脫髮、厭食疲乏、噁心嘔吐、白細胞下降等,多數患者能耐受.結論多西他賽聯閤錶柔吡星治療乳腺癌的療效肯定,毒副反應小,患者能耐受,值得推廣.
목적탐토다서타새연합표유필성치료유선암적료효급불량반응.방법장120례만기유선암환자수궤분위관찰조화대조조,매조60례.관찰조채용다서타새연합표유필성치료;대조조채용배린선알연합5-불뇨밀정、아매소치료,비교량조환자적림상료효급독부반응.결과관찰조CR 8례, PR36례,근기총유효솔위73.3%(44/60),현저고우대조조적근기총유효솔26.7%(16/60)( P <0.05);불량반응위탈발、염식피핍、악심구토、백세포하강등,다수환자능내수.결론다서타새연합표유필성치료유선암적료효긍정,독부반응소,환자능내수,치득추엄.
Objective To assess the efficacy and safety of docetaxel plus pirarubicin(THP) in treating breast cancer. Methods 120 patients with advanced carcinoma of large intestine were randomly divided into trial group and control group, and each group was 60 patients. Patients in the trial group were treated with docetaxel plus pirarubicin(THP) while the control group were treated with the combination of cyclophosphamide(CTX)+ doxorubicin(ADM)+Fluorouracil(5-FU). Then the the clinical curative effects and toxical effects in two groups were compared. Results For the trial group, 8 patient reached complete response (CR), 36 partial response (PR). The overal response rate (CR+PR) was 73.3% (44/60), and looked higher than that of controled group (26.7%) (16/60) (P<0.05). Conclusion docetaxel plus pirarubicin(THP) in treating breast cancer had higher response rate, lower toxicity, longer median survival and better quality of life.